newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On April 1, 2026, Praxis Precision Medicines' Compensation Committee granted restricted stock unit awards covering 3,558 shares of common stock.
  • The awards were given to eighteen new non-executive employees under the 2024 Inducement Plan.
  • The grants were made pursuant to Nasdaq Listing Rule 5635(c)(4) as inducements material to the employees' employment.
  • The 2024 Inducement Plan is exclusively used for equity awards to individuals who were not previously employees or returned after a bona fide non-employment period.
  • The restricted stock units will vest in four equal annual installments contingent on continued employment.
  • Praxis is a CNS precision neuroscience biopharmaceutical company developing therapies for disorders involving neuronal excitation-inhibition imbalance.
  • The company utilizes its Cerebrum™ small molecule platform & Solidus™ antisense oligonucleotide platform to advance a diversified portfolio including four late-stage product candidates.